id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S12619 R47575 |
Van Marter (Levetiracetam) (Controls unexposed, disease free), 2021 | Prematurity - Moderate (28-33 wk gestational age) | at least 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No |
2.21 [0.20;24.77] C excluded (control group) |
2/97 1/106 | 3 | 97 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12616 R47557 |
Van Marter (Levetiracetam) (Controls unexposed, sick), 2021 | Prematurity - Moderate (28-33 wk gestational age) | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.29 [0.03;3.47] C | 2/97 1/15 | 3 | 97 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10072 R36658 |
Coste (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020 | Gestational age at birth (< 32 WA) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
2.99 [1.08;8.29] C excluded (control group) |
7/621 8/2,108 | 15 | 621 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7807 R23106 |
Coste (Levetiracetam) (Controls unexposed, NOS), 2020 | Gestational age at birth (27–31 WA) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 1.93 [0.87;4.32] C | 6/621 8,584/1,710,441 | 8,590 | 621 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 1.10 [0.20;5.96] | 8,593 | 718 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Levetiracetam) (Controls unexposed, sick; 2: Levetiracetam) (Controls unexposed, NOS;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 10072, 12619